新型抗肥胖疗法及其不同的效果和安全性概况：批判性综述
Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview.
作者信息
Telci Caklili Ozge, Cesur Mustafa, Mikhailidis Dimitri P, Rizzo Manfredi
机构信息
Department of Endocrinology and Metabolism, Faculty of Medicine, University of Istanbul, Istanbul, Türkiye.
Department of Endocrinology and Metabolism, Ankara Guven University Hospital, Ankara, Türkiye.
出版信息
Diabetes Metab Syndr Obes. 2023 Jun 14;16:1767-1774. doi: 10.2147/DMSO.S392684. eCollection 2023.
Abstract
Obesity has become an epidemic and a worldwide problem and its treatment is ever-evolving. Apart from diet and exercise, medication and surgery are other options. After disappointing side effects of various obesity drugs, new treatments showed promising results. This review discusses the following anti-obesity drugs: liraglutide, semaglutide, tirzepatide, orlistat, as well as the phentermine/topiramate and bupropion/naltrexone combinations. These drugs have been approved by the Food and Drug Administration (FDA) for weight reduction except for tirzepatide which is still under evaluation. Efficacy and tolerable safety profiles of some of these drugs contribute to the management of obesity and reduce the complications associated with this chronic disease.
摘要
肥胖已成为一种流行病和全球性问题，其治疗方法也在不断发展。除饮食和运动外，药物治疗和手术也是其他选择。在各种减肥药出现令人失望的副作用后，新的治疗方法显示出了有希望的结果。本综述讨论了以下抗肥胖药物：利拉鲁肽、司美格鲁肽、替尔泊肽、奥利司他，以及苯丁胺/托吡酯和安非他酮/纳曲酮组合。除仍在评估中的替尔泊肽外，这些药物均已获得美国食品药品监督管理局（FDA）批准用于减肥。其中一些药物的疗效和可耐受的安全性有助于肥胖的管理，并减少与这种慢性病相关的并发症。
相似文献
1
Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview.新型抗肥胖疗法及其不同的效果和安全性概况：批判性综述
Diabetes Metab Syndr Obes. 2023 Jun 14;16:1767-1774. doi: 10.2147/DMSO.S392684. eCollection 2023.
2
Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy.肥胖症：新的全球性流行疾病 药物治疗、个体化治疗的机遇与限制。
Endocr Metab Immune Disord Drug Targets. 2020;20(8):1232-1243. doi: 10.2174/1871530320666200515112853.
3
Drugs for Treating Obesity.肥胖症治疗药物
Handb Exp Pharmacol. 2022;274:387-414. doi: 10.1007/164_2021_560.
4
Drug treatment of obesity: current status and future prospects.肥胖症的药物治疗：现状与未来展望。
Eur J Intern Med. 2015 Mar;26(2):89-94. doi: 10.1016/j.ejim.2015.01.005. Epub 2015 Jan 26.
5
Long-term effects of weight-reducing drugs in people with hypertension.减肥药物对高血压患者的长期影响。
Cochrane Database Syst Rev. 2016 Mar 2;3:CD007654. doi: 10.1002/14651858.CD007654.pub4.
6
Current and emerging pharmacotherapies for obesity in Australia.澳大利亚当前和新兴的肥胖症药物治疗方法。
Obes Res Clin Pract. 2017 Sep-Oct;11(5):501-521. doi: 10.1016/j.orcp.2017.07.002. Epub 2017 Aug 14.
7
Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment.抗肥胖药物的估计最低价格和全国最低可得价格：提高可承受性和治疗可及性
Obesity (Silver Spring). 2023 May;31(5):1270-1279. doi: 10.1002/oby.23725. Epub 2023 Feb 23.
8
FDA-Approved Pharmacotherapy for Weight Loss Over the Last Decade.过去十年中获得美国食品药品监督管理局（FDA）批准的减肥药物疗法。
Cureus. 2022 Sep 17;14(9):e29262. doi: 10.7759/cureus.29262. eCollection 2022 Sep.
9
A narrative review of approved and emerging anti-obesity medications.已批准和新出现的抗肥胖药物的叙述性综述。
Saudi Pharm J. 2023 Oct;31(10):101757. doi: 10.1016/j.jsps.2023.101757. Epub 2023 Aug 24.
10
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity.AGA 临床实践指南：药物干预成人肥胖症。
Gastroenterology. 2022 Nov;163(5):1198-1225. doi: 10.1053/j.gastro.2022.08.045. Epub 2022 Oct 20.
引用本文的文献
1
Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland.胰高血糖素样肽-1（GLP-1）受体激动剂司美格鲁肽和利拉鲁肽治疗肥胖2型糖尿病患者的相对有效性和安全性：波兰一项前瞻性观察队列研究
Diabetes Metab Syndr Obes. 2025 Aug 7;18:2723-2738. doi: 10.2147/DMSO.S531697. eCollection 2025.
2
PEG-Coated Ceria-Zirconia Nanoparticle Prevent Weight Gain and Obesity-Related Organ Damage Through Autophagy Flux Activation and ROS Scavenging.聚乙二醇包覆的二氧化铈-氧化锆纳米颗粒通过激活自噬通量和清除活性氧来预防体重增加和肥胖相关器官损伤。
Int J Nanomedicine. 2025 Jun 26;20:8305-8326. doi: 10.2147/IJN.S510541. eCollection 2025.
3
Mechanisms underlying obesity-malignancy connection: a systematic narrative review.肥胖与恶性肿瘤关联的潜在机制：一项系统性叙述性综述
J Physiol Biochem. 2025 May 23. doi: 10.1007/s13105-025-01084-9.
4
Clinical studies on anti-obesity medications in Arab countries.阿拉伯国家抗肥胖药物的临床研究。
Saudi Med J. 2025 May;46(5):459-477. doi: 10.15537/smj.2025.46.5.20250126.
5
Role of pancreatic lipase inhibition in obesity treatment: mechanisms and challenges towards current insights and future directions.胰脂肪酶抑制在肥胖治疗中的作用：当前见解的机制与挑战及未来方向
Int J Obes (Lond). 2025 Mar;49(3):492-506. doi: 10.1038/s41366-025-01729-1. Epub 2025 Feb 27.
6
Insights into the neurobiology of weight loss after bariatric surgery and GLP-1R agonists.对减肥手术后体重减轻及胰高血糖素样肽-1受体激动剂的神经生物学见解。
Neuropharmacology. 2025 Mar 1;265:110269. doi: 10.1016/j.neuropharm.2024.110269. Epub 2024 Dec 14.
7
Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group.心脏代谢连续体的现代管理：从超重/肥胖到糖尿病前期/2型糖尿病。东欧和南欧糖尿病与肥胖专家组的建议。
Diabetes Ther. 2024 Sep;15(9):1865-1892. doi: 10.1007/s13300-024-01615-5. Epub 2024 Jul 11.
8
The Regulation of Metabolic Homeostasis by Incretins and the Metabolic Hormones Produced by Pancreatic Islets.肠促胰岛素和胰岛产生的代谢激素对代谢稳态的调节
Diabetes Metab Syndr Obes. 2024 Jun 13;17:2419-2456. doi: 10.2147/DMSO.S415934. eCollection 2024.
本文引用的文献
1
Semaglutide in Obesity: Unmet Needs in Men.司美格鲁肽治疗肥胖症：男性未满足的需求
Diabetes Ther. 2023 Mar;14(3):461-465. doi: 10.1007/s13300-022-01360-7. Epub 2023 Jan 7.
2
Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials.胰高血糖素样肽-1受体激动剂治疗非糖尿病成年肥胖患者的比较效果：一项随机临床试验的网状荟萃分析
Obes Rev. 2023 Mar;24(3):e13543. doi: 10.1111/obr.13543. Epub 2022 Dec 29.
3
Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.胰高血糖素样肽-1受体激动剂及双重葡萄糖依赖性促胰岛素多肽/胰高血糖素样肽-1受体激动剂在肥胖/代谢综合征、糖尿病前期/糖尿病及非酒精性脂肪性肝病治疗中的应用——当前证据
J Cardiovasc Pharmacol Ther. 2022 Jan-Dec;27:10742484221146371. doi: 10.1177/10742484221146371.
4
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023.9. 血糖治疗的药物学方法：2023 年糖尿病的护理标准。
Diabetes Care. 2023 Jan 1;46(Suppl 1):S140-S157. doi: 10.2337/dc23-S009.
5
Marked weight loss on liraglutide 3.0 mg: Real-life experience of a Swiss cohort with obesity.利拉鲁肽 3.0 毫克治疗肥胖的显著体重减轻：瑞士队列的真实临床经验。
Obesity (Silver Spring). 2023 Jan;31(1):74-82. doi: 10.1002/oby.23596. Epub 2022 Dec 7.
6
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.超重或肥胖成年人中司美格鲁肽的 2 年疗效：STEP 5 试验。
Nat Med. 2022 Oct;28(10):2083-2091. doi: 10.1038/s41591-022-02026-4. Epub 2022 Oct 10.
7
The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact.新冠疫情与肥胖症双重大流行：双向影响
Diabetes Ther. 2022 Oct;13(10):1723-1736. doi: 10.1007/s13300-022-01311-2. Epub 2022 Aug 27.
8
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.替尔泊肽单药治疗与度拉鲁肽治疗日本 2 型糖尿病患者的疗效和安全性比较（SURPASS J-单药）：一项双盲、多中心、随机、3 期临床试验。
Lancet Diabetes Endocrinol. 2022 Sep;10(9):623-633. doi: 10.1016/S2213-8587(22)00188-7. Epub 2022 Jul 30.
9
Tirzepatide Once Weekly for the Treatment of Obesity.司美格鲁肽每周一次治疗肥胖症。
N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4.
10
Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study.利拉鲁肽对肥胖2型糖尿病患者心脏代谢参数的改善作用大于非肥胖患者：一项为期18个月的真实世界前瞻性研究。
Diabetes Ther. 2022 Mar;13(3):453-464. doi: 10.1007/s13300-022-01217-z. Epub 2022 Feb 15.
Zotero 插件